BioPharmSignal logoBioPharmSignal

Biotech News

aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

aTyr Pharma (ATYR)aTyr PharmaEarnings

Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis. Phase 2 EFZO-CONNECT™ study of efzofitimod in systemic sclerosis-related interstitial lung disease (SSc-ILD) on

Open original release

Related news

ATYRaTyr Pharma2026-05-15 12:00 EST

aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

IMVTImmunovant2026-05-20 11:00 EST

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026

BNTXBioNTech2026-07-21 10:45 EST

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

ZURAZura Bio2026-05-07 11:30 EST

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

BNTXBioNTech2026-05-05 10:45 EST

BioNTech Announces First Quarter 2026 Financial Results and Corporate Update

NRIXNurix Therapeutics2026-04-08 10:00 EST

Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

CLDXCelldex Therapeutics2026-05-07 20:01 EST

Celldex Reports First Quarter Financial Results and Provides Corporate Update

ZURAZura Bio2026-03-19 20:05 EST

Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates

GRIGRI Bio2026-05-14 08:35 EST

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline

IMVTImmunovant2026-05-11 20:05 EST

Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026

View all latest news

aTyr Pharma

aTyr Pharma is a biotechnology company focused on extracellular biology and inflammatory disease. Its story is centered on using novel biology to address serious immune-mediated conditions.

Recent company news

ATYRaTyr Pharma2026-05-15 12:00 EST

aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

ATYRaTyr Pharma2026-05-13 20:01 EST

aTyr Pharma to Participate in Upcoming Investor Conferences

ATYRaTyr Pharma2026-05-11 20:01 EST

aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting

ATYRaTyr Pharma2026-03-05 21:01 EST

aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

ATYRaTyr Pharma2026-02-20 21:01 EST

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
0.49 USD
Market cap
50.99M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States